SalaryGuide
SalariesCompaniesJobs
AboutPricingBlogFor Employers

Marketing jobs

7 marketing jobs

Regeneron logo
4 weeks ago

Senior Manager, Oncology Marketing

Regeneron

Sleepy Hollow, NY (Hybrid)$134K/yr – $219K/yr
Regeneron logo
5 weeks ago

Associate Director, Consumer Marketing - EOE

Regeneron

Sleepy Hollow, NY (Unknown)$157K/yr – $257K/yr
Regeneron logo
7 weeks ago

Director, Scientific Marketing Lead (NSCLC)

Regeneron

Sleepy Hollow, NY (Hybrid)Full time$183K/yr – $305K/yr
Regeneron logo
2 months ago

Director, HCP Marketing - Dermatology

Regeneron

Sleepy Hollow, NY (Unknown)$183K/yr – $305K/yr
Regeneron logo
2 months ago

Director, Global Commercial Planning & Strategy (Rare Disease)

Regeneron

USA (Unknown)$183K/yr – $305K/yr
Regeneron logo
2 months ago

Director, Market Access Analytics

Regeneron

Sleepy Hollow, NY (Unknown)$183K/yr – $305K/yr
Regeneron logo
4 months ago

Manager, Ophthalmology Marketing

Regeneron

Sleepy Hollow, NY (Unknown)$115K/yr – $187K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

7 jobs
Regeneron logo

Senior Manager, Oncology Marketing

Regeneron

Sleepy Hollow, NY (Hybrid)

$134K/yr - $219K/yrIn-houseSenior level5+ years exp.
4 weeks ago
Regeneron logo

Associate Director, Consumer Marketing - EOE

Regeneron

Sleepy Hollow, NY (Unknown)

$157K/yr - $257K/yrIn-houseSenior level10+ years exp.
5 weeks ago
Regeneron logo

Director, Scientific Marketing Lead (NSCLC)

Regeneron

Sleepy Hollow, NY (Hybrid)

$183K/yr - $305K/yrIn-houseFull-timeDirector/executive12+ years exp.
7 weeks ago
Regeneron logo

Director, HCP Marketing - Dermatology

Regeneron

Sleepy Hollow, NY (Unknown)

$183K/yr - $305K/yrIn-houseSenior level12+ years exp.
2 months ago
Regeneron logo

Director, Global Commercial Planning & Strategy (Rare Disease)

Regeneron

USA (Unknown)

$183K/yr - $305K/yrIn-houseDirector/executive12+ years exp.
2 months ago
Regeneron logo

Director, Market Access Analytics

Regeneron

Sleepy Hollow, NY (Unknown)

$183K/yr - $305K/yrIn-houseDirector/executive12+ years exp.
2 months ago
Regeneron logo

Manager, Ophthalmology Marketing

Regeneron

Sleepy Hollow, NY (Unknown)

$115K/yr - $187K/yrIn-houseManager3+ years exp.
4 months ago
Regeneron logo
Regeneron

Senior Manager, Oncology Marketing

Sleepy Hollow, NY (Hybrid)

$134K/yr – $219K/yrSenior Level5+ years exp

Posted 4 weeks ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own the NSCLC field marketing execution from non-personal promotion planning through vendor management and field integration, ensuring timely materials, budget reconciliation, and cross‑functional alignment.

  • Lead non-personal promotion plans, timelines, and outputs
  • Manage digital and field communications and vendors
  • Support marketing operations including Veeva CRM and inventory management

Job Description

Responsibilities

  • Support execution of NSCLC customer engagement activities and non-personal promotion programs
  • Coordinate development of NSCLC non-personal promotion plans, tactical timelines, outputs, data triggers, and budgets
  • Create downstream field-based materials and selected original field-based pieces as identified and needed
  • Manage vendors supporting digital and non-personal communications, including e-blasts, rep-triggered emails, CRM, banner ads, and related channels
  • Coordinate non-personal and field team integration activities, including field communications
  • Collect and reconcile budget inputs with HCP and Scientific marketing leads monthly
  • Support marketing operations for the team, including Veeva CRM platform management, print and digital inventory management, and meeting management
  • Work with agency partners on label updates and new launches for HCP promotional materials, including website updates
  • Serve as Review Committee captain by coordinating RC prioritization, meetings, submissions, and follow-up for the NSCLC team

Requirements

  • Bachelor's degree required; MBA preferred
  • 5+ years of U.S. commercial experience in pharmaceutical/biotech marketing, product management, or related areas
  • Field experience is preferred
  • Demonstrated ability to work effectively and efficiently with team members and across departments to support alignment, consistency, and collaboration
  • Strong project and process management skills with attention to detail
  • Must be proactive and able to prioritize and operate in a fast-paced environment
  • Experience with media planning, digital customer engagement, and digital engagement plan execution preferred
  • Good problem-solving ability with strong interpersonal skills both internally and externally
  • Ability to grasp complex scientific concepts and clinical data
  • Must be willing to travel approximately 25%, including weekends for conferences and meetings, as needed
Regeneron logo

Regeneron

3.9 Glassdoor

At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.

Founded in 1988
Tarrytown, New York, USA
16K employees (772 in marketing)
www.regeneron.com
73% recommend to a friend
88% CEO approval

Salaries

Posted range

$134K/yr – $219K/yr

Taken straight from the job posting.

See all Regeneron salaries

Marketing Team

Marketing Team Size
688 (4% of company)
Median Tenure
4.8 years
Marketing Roles Posted (Last 30 Days)
3

Funding

Total Funding
$15.9M
Last Raise
$2M
Post IPO Equity, 2 years ago

Funding History

  • Jul 2024
    Post IPO Equity • $2M
  • Oct 2023
    Post IPO Equity • $5M
  • Aug 2016
    Post IPO Equity • $8.9M

Traffic Signals

Monthly Visitors
355.2K
Monthly Google Ads Budget
$56.8K
Traffic Source Mix
Search
40.8%
Direct
42.2%
Referral
9.5%
Social
6.3%
Paid
1%

Headcount Trend

Current headcount: ~16.5K

Recent News

Regeneron's experimental therapy combo effective in untreated cancer patients
Dec 6, 2025 • Reuters
Regeneron inks gene editing deal with startup Tessera
Dec 1, 2025 • BioPharma Dive
Regeneron makes $150M bet on Tessera's rare disease gene writing prospect
Dec 1, 2025 • Fierce Biotech
Regeneron Makes $275M Gene Editing Play With Tessera Partnership Targeting AATD
Dec 1, 2025 • BioSpace
Regeneron Pharmaceuticals (REGN): Examining Valuation After Recent Share Price Momentum
Nov 25, 2025 • Yahoo Finance
Regeneron wins 2 Eylea nods, ramping up competition with Roche
Nov 20, 2025 • Fierce Pharma
Regeneron pledges $2B to convert former magazine factory into drug plant: NY governor
Nov 18, 2025 • Fierce Pharma
Governor Hochul Announces Regeneron to Invest More Than $2 Billion Into Saratoga County Facility, Creating 1,000 New Jobs
Nov 13, 2025 • Empire State Development (ESD) (.gov)
Regeneron to build $2 billion factory in Saratoga County, create 1,000 jobs
Nov 13, 2025 • Times Union
Gov. Hochul: Regeneron to invest more than $2B in new Spa City facility
Nov 13, 2025 • WRGB
Regeneron to expand into Saratoga Co. with new facility
Nov 13, 2025 • NEWS10 ABC
Regeneron (REGN): Revisiting Valuation After Recent 16% Share Price Rally
Nov 11, 2025 • Yahoo Finance
What Catalysts Are Driving the Changing Narrative for Regeneron?
Oct 30, 2025 • Yahoo Finance
Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies
Oct 29, 2025 • Fierce Biotech
Regeneron Adds Fuel to Hot Healthcare Trade. Which Stocks Could Follow it Higher?
Oct 29, 2025 • Barron's
Regeneron receives another CRL for its Eylea 8 mg
Oct 29, 2025 • Ophthalmology Times
Regeneron tops quarterly estimates, plans to resubmit Eylea application
Oct 28, 2025 • Reuters
Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts
Oct 28, 2025 • Investor's Business Daily
Regeneron (NASDAQ:REGN) Surprises With Strong Q3
Oct 28, 2025 • Yahoo Finance
A Look at Regeneron Pharmaceuticals’s Valuation Following Key European Regulatory Win for Libtayo
Oct 26, 2025 • Yahoo Finance
Regeneron Cans 2seventy-Acquired CAR T Candidate for Lymphoma in ‘Strategic’ Move
Oct 24, 2025 • BioSpace
Regeneron does 180 on 2seventy lymphoma CAR-T, halting study and nixing further development
Oct 23, 2025 • Fierce Biotech
Regeneron settles Eylea patent dispute with Celltrion, allowing another biosimilar to launch at end of 2026
Oct 22, 2025 • Fierce Pharma
Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge
Oct 13, 2025 • Yahoo Finance
Regeneron’s Gene Therapy DB-OTO Improves Speech Perception in Children With Otoferlin-Related Hearing Loss
Oct 13, 2025 • CGTLive®
Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy
Oct 12, 2025 • BioPharma Dive
Regeneron amplifies CHORD progression, sharing updated data on hearing loss gene therapy
Oct 12, 2025 • Fierce Biotech
Regeneron scores in adjuvant skin cancer | ApexOnco - Clinical Trials news and analysis
Oct 9, 2025 • Oncology Pipeline
Regeneron, needing a turnaround, gains new use for cancer drug
Oct 9, 2025 • BioPharma Dive
FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery
Oct 9, 2025 • Pharmaceutical Technology
US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer
Oct 8, 2025 • Reuters
Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management
Oct 2, 2025 • Yahoo Finance
Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials
Oct 1, 2025 • Yahoo Finance
6 FDA Decisions to Watch For in Q4
Sep 29, 2025 • BioSpace
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
Sep 29, 2025 • BioSpace
Regeneron announces U.S. FDA approved Evkeeza ANGPTL3 antibody
Sep 26, 2025 • thefly.com
U.S. Food and Drug Administration Approves Evkeeza (Evkeeza-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
Sep 26, 2025 • MarketScreener
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
Sep 26, 2025 • Regeneron Pharmaceuticals, Inc.
COPD is still less likely than heart disease or lung cancer to be viewed as a leading cause of death
Sep 26, 2025 • EIN Presswire
FDA Expands Use Of Regeneron's Evkeeza To Infants With Rare Cholesterol Disorder
Sep 26, 2025 • Benzinga.com
Rheumatoid Arthritis Therapeutics Market Trends Analysis Report 2025-2033 by Molecule (Pharmaceuticals, Biopharmaceuticals), by Sales Channel (Prescription, Over-the-Counter)
Sep 26, 2025 • Research and Markets
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
Sep 26, 2025 • MarketScreener
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sep 26, 2025 • Pharmafile
Why Regeneron (REGN) Stock Is Down Today
Sep 23, 2025 • Yahoo Finance
US FDA declines to approve Scholar Rock’s muscle weakness drug; shares fall
Sep 23, 2025 • Investing.com
FDA rejects Scholar Rock's SMA drug, citing issues at Novo's Catalent Indiana site
Sep 23, 2025 • FiercePharma
Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
Sep 23, 2025 • PharmiWeb
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
Sep 23, 2025 • Benzinga.com
Labviva Kicks Off Smart Lab of the Future Tour
Sep 23, 2025 • Labviva
Much Maligned Manufacturing Site Trips Up Scholar Rock’s Spinal Muscular Atrophy Drug
Sep 23, 2025 • BioSpace
Wall Street Pauses For A Breather, Small Caps Soar: What's Moving Markets Tuesday?
Sep 23, 2025 • Benzinga.com
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
Sep 22, 2025 • BioSpace
FDA Delays Key Sanofi Multiple Sclerosis Drug Decision
Sep 22, 2025 • Benzinga.com
Regeneron, Sanofi announce CHMP opinion recommending Dupixent approval
Sep 22, 2025 • thefly.com
How the Narrative for Regeneron Has Shifted with Pipeline Wins and Analyst Optimism
Sep 20, 2025 • Yahoo Finance
Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study
Sep 19, 2025 • Reuters
Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
Sep 17, 2025 • Yahoo Finance
Regeneron drug reduces errant bone growth in ultra-rare skeletal condition
Sep 17, 2025 • statnews.com
Regeneron reports phase 3 win in ultrarare disease, bouncing back to spark race to FDA
Sep 17, 2025 • Fierce Biotech
Regeneron's rare bone disorder drug succeeds in late-stage trial
Sep 17, 2025 • Reuters
Regeneron announces primary endpoint met in Phase 3 OPTIMA trial
Sep 17, 2025 • thefly.com
Regeneron announces updated analyses from Phase 2 COURAGE trial
Sep 17, 2025 • thefly.com
Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies in Atopic Dermatitis, Asthma, CRSwNP, and Others | DelveInsight
Sep 17, 2025 • PR Newswire
Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies in Atopic Dermatitis, Asthma, CRSwNP, and Others | DelveInsight
Sep 17, 2025 • PR Newswire UK
Regeneron Pharmaceuticals, Inc. Announces Updated Analyses from the Ongoing Phase 2 Cloud Trial Investigating Novel Combination of Semaglutide (Glp-1 Receptor Agonist) and Trevogrumab (Anti-Myostatin)
Sep 17, 2025 • MarketScreener
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
Sep 17, 2025 • MarketScreener
Regeneron, Elf Beauty, Eli Lilly
Sep 17, 2025 • Reuters
Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial
Sep 16, 2025 • Yahoo Finance
Pozelimab and cemdisiran combo holds potential in MG market
Sep 16, 2025 • Pharma Letter
Senhwa Biosciences' CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market
Sep 16, 2025 • PR Newswire
BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN)
Sep 15, 2025 • Yahoo Finance
Biotech Sector May Flip to Market Leader by Year-End
Sep 15, 2025 • MarketBeat
BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT
Sep 13, 2025 • Yahoo Finance
Phase III success for Regeneron signals pozelimab and cemdisiran’s entry into MG market
Sep 11, 2025 • Clinical Trials Arena
Beyond MariTide: Amgen Makes Portfolio Play Amid Scrutiny of Obesity Prospect
Sep 10, 2025 • BioSpace
Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful
Sep 10, 2025 • BioSpace
Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar
Sep 9, 2025 • Sandoz
Regeneron’s cat and birch allergy mAbs score in Phase III trials
Sep 9, 2025 • Clinical Trials Arena
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’
Sep 9, 2025 • BioSpace
Sandoz and Regeneron reach agreement over biosimilar dispute
Sep 9, 2025 • Ophthalmology Times
Regeneron ends patent fight with Sandoz over Eylea biosimilar
Sep 9, 2025 • FirstWord Pharma
With settlement, Sandoz can launch its biosimilar to Regeneron's Eylea by end of 2026
Sep 9, 2025 • Fierce Pharma
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Sep 9, 2025 • Bragar Eagel & Squire
Regeneron announces follow-up results on Phase 3 EMPOWER-Lung 3 trial
Sep 9, 2025 • thefly.com
With Asthma-Related ER Visits Increasing, AAFA Names 2025 Asthma Capitals
Sep 9, 2025 • Morningstar.com
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
Sep 9, 2025 • Regeneron Pharmaceuticals, Inc.
Sandoz reaches agreement with Regeneron over patent litigation
Sep 9, 2025 • thefly.com
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
Sep 9, 2025 • Morningstar.com
Regeneron at Morgan Stanley Conference: Strategic Pipeline Potential
Sep 8, 2025 • Investing.com
Regeneron's allergen-blocking antibodies score phase 3 wins against cat, pollen allergies
Sep 8, 2025 • Fierce Biotech
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
Sep 8, 2025 • BioSpace
What's Happening With Regeneron Pharmaceuticals Stock On Monday?
Sep 8, 2025 • Benzinga.com
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
Sep 8, 2025 • Morningstar.com
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
Sep 8, 2025 • Regeneron Pharmaceuticals, Inc.
How Positive Phase 3 Cemdisiran Results at Regeneron (REGN) Have Changed Its Investment Story
Sep 6, 2025 • Yahoo Finance
'Several concerning observations': FDA sheds more light on reasons it rejected drugs
Sep 5, 2025 • FierceBiotech
Sanofi phase 3 eczema win falls short of analyst expectations
Sep 4, 2025 • FierceBiotech
Merck KGaA names new R&D chief as it doubles down on Africa growth
Sep 3, 2025 • Pharma Letter
Merck names new R&D chief for healthcare business
Sep 3, 2025 • pharmaphorum
Evercore ISI Maintains a Buy on Regeneron Pharmaceuticals (REGN) With a $750 PT
Sep 2, 2025 • Yahoo Finance

Links

www.regeneron.comLinkedInX (Twitter)Crunchbase

This role is listed on SalaryGuide for informational purposes. SalaryGuide is not the employer, recruitment agency, or hiring representative for this position. Hiring decisions and the application process are managed by the employer. SalaryGuide will never ask candidates to pay to apply for a job or request bank details or identification documents as part of an application.